Strict ovarian CA screening adherence called for in high-risk

This article originally appeared here.
Strict Ovarian CA Screening Adherence Called for in High-Risk
Strict Ovarian CA Screening Adherence Called for in High-Risk

(HealthDay News) -- For women at higher risk for ovarian and/or fallopian tube cancer (OC/FTC), annual screening offers high sensitivity for detection of incident cancers, but few of these cancers are stage I or II, according to research published online Dec. 3 in the Journal of Clinical Oncology.

Between 2002 and 2008, Adam N. Rosenthal, M.D., Ph.D., of Barts and the London School of Medicine and Dentistry, and colleagues screened 3,563 women who were estimated to be at a 10 percent or higher lifetime risk of OC/FTC. Women were evaluated using transvaginal ultrasound and serum CA125 screening and followed prospectively.

The researchers found that, at one year after the last annual screening, the sensitivity for detection of incident OC/FTC was 81.3 or 87.5 percent if occult cancers were classified as false negatives or true positives, respectively. For incident screening, the positive and negative predictive values were 25.5 and 99.9 percent, respectively. There were 13 incident screen-detected cases of OC/FTC; only four of these were stage I or II. Women who were not screened in the year before diagnosis were significantly more likely to have stage IIIc disease or higher compared with those who had been screened the year before (85.7 versus 26.1 percent). In prevalent and incident cancer, the median time between detection screen and surgical intervention was 79 days.

"These results in the high-risk population highlight the need for strict adherence to [a] screening schedule," the authors write. "Screening more frequently than annually, with prompt surgical intervention, seems to offer a better chance of early-stage detection."

Several authors disclosed financial ties to medical and diagnostic technology companies.

Abstract
Full Text (subscription or payment may be required)
Editorial

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs